- Home
- BSM vs DYN Comparison
BSM vs DYN Comparison
Compare BSM & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- DYN
- Stock Information
- Founded
- BSM 1876
- DYN 1984
- Country
- BSM United States
- DYN United States
- Employees
- BSM N/A
- DYN N/A
- Industry
- BSM Oil & Gas Production
- DYN Medicinal Chemicals and Botanical Products
- Sector
- BSM Energy
- DYN Health Care
- Exchange
- BSM Nasdaq
- DYN Nasdaq
- Market Cap
- BSM 3.1B
- DYN 2.6B
- IPO Year
- BSM 2015
- DYN 2020
- Fundamental
- Price
- BSM $15.35
- DYN $9.91
- Analyst Decision
- BSM Hold
- DYN Strong Buy
- Analyst Count
- BSM 2
- DYN 12
- Target Price
- BSM $16.00
- DYN $47.73
- AVG Volume (30 Days)
- BSM 305.7K
- DYN 2.1M
- Earning Date
- BSM 05-05-2025
- DYN 05-01-2025
- Dividend Yield
- BSM 9.79%
- DYN N/A
- EPS Growth
- BSM N/A
- DYN N/A
- EPS
- BSM 1.15
- DYN N/A
- Revenue
- BSM $426,968,000.00
- DYN N/A
- Revenue This Year
- BSM $15.21
- DYN N/A
- Revenue Next Year
- BSM $8.39
- DYN N/A
- P/E Ratio
- BSM $13.35
- DYN N/A
- Revenue Growth
- BSM N/A
- DYN N/A
- 52 Week Low
- BSM $13.78
- DYN $8.94
- 52 Week High
- BSM $16.92
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- BSM 57.64
- DYN 33.59
- Support Level
- BSM $15.11
- DYN $10.72
- Resistance Level
- BSM $15.43
- DYN $12.00
- Average True Range (ATR)
- BSM 0.19
- DYN 0.80
- MACD
- BSM 0.01
- DYN -0.13
- Stochastic Oscillator
- BSM 75.49
- DYN 25.06
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.